China Opens New Registration Regs For Comment, Industry Urged To 'Weigh In'
Following the passing of a new Pharmaceutical Administration Law, which will take effect on 1 December, China’s National Medical Products Administration has now released a second draft of its Drug Registration Regulations, and observers are urging stakeholders to actively submit comments on the highly important framework.
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.
In a shocking and revealing account, a primary investigator of the front-runner antiviral drug for the coronavirus in China expresses concerns over finding enough patients for the study Wuhan, the outbreak's epicenter.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.